ArticleThe Journal of antimicrobial chemotherapy2012
Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence.
Article in The Journal of antimicrobial chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 120 citations in OpenAlex.
- Ag85A-PEGylated Propolis Nanoparticles Exhibit Intracellular Antimycobacterial and Host-Protective Activities AgainstInternational journal of molecular sciences · 2026Article
- Systems-level characterization of EGFR kinase inhibitors reveals heterogeneous effects on Mtb-macrophage interactions.bioRxiv : the preprint server for biology · 2025Article
- TowardMicroorganisms · 2024Review
- Quantification of Mycobacterium tuberculosis Growth in Cell-Based Infection Assays by Time-Lapse Fluorescence Microscopy.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Nano-Delivery System of Ethanolic Extract of Propolis TargetingNanomaterials (Basel, Switzerland) · 2023Article
- 10-DEBC Hydrochloride as a Promising New Agent against Infection ofInternational journal of molecular sciences · 2022Article
- Improved Conventional and New Approaches in the Diagnosis of Tuberculosis.Frontiers in microbiology · 2022Review
- Evolution of Antibacterial Drug Screening Methods: Current Prospects for Mycobacteria.Microorganisms · 2021Review
- Clomiphene Citrate Shows Effective and Sustained Antimicrobial Activity againstInternational journal of molecular sciences · 2021Article
- Exploration of Synergistic Action of Cell Wall-Degrading Enzymes against Mycobacterium tuberculosis.Antimicrobial agents and chemotherapy · 2021Article
- Article
- A high-throughput screening assay based on automated microscopy for monitoring antibiotic susceptibility of Mycobacterium tuberculosis phenotypes.BMC microbiology · 2021Article
- Isolation of a Novel Polyketide fromMolecules (Basel, Switzerland) · 2021Article
- Nanomotion Detection-Based Rapid Antibiotic Susceptibility Testing.Antibiotics (Basel, Switzerland) · 2021Review
- Article
- Screening of Fungi for Antimycobacterial Activity Using a Medium-Throughput Bioluminescence-Based Assay.Frontiers in microbiology · 2021Article
- Article
- A lux-based Staphylococcus aureus bioluminescence screening assay for the detection/identification of antibiotics and prediction of antibiotic mechanisms.The Journal of antibiotics · 2020Article
- Preclinical Models of Nontuberculous Mycobacteria Infection for Early Drug Discovery and Vaccine Research.Pathogens (Basel, Switzerland) · 2020Review
- Adjunctive Host-Directed Therapy With Statins Improves Tuberculosis-Related Outcomes in Mice.The Journal of infectious diseases · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
objectivesTuberculosis drug development is hampered by the slow growth of Mycobacterium tuberculosis. Bioluminescence, light produced by an enzymatic reaction, constitutes a rapid and highly sensitive measurement of cell metabolic function that can be used as an indirect marker of cell viability in drug screening assays. The aim of this work was to validate and standardize the use of luminescent M. tuberculosis strains to test the activity of antibacterial drugs in vitro and inside macrophages in a 96-well format.
methodsWe have used strains that express the bacterial lux operon and therefore do not require exogenous substrate to produce light, as well as strains expressing the firefly luciferase that need luciferin substrate. Results were compared with those obtained using the resazurin reduction assay and cfu plating.
resultsUsing bioluminescence we were able to reduce the time required to measure the MIC and bactericidal concentrations of antimicrobials to just 3 and 6 days, respectively. Furthermore, antibacterial activity against intracellular mycobacteria was detected within 2 days post-infection. Results were comparable to those obtained by conventional methods.
conclusionsWe have developed a simple and rapid method for screening antimycobacterial drugs in culture and in macrophages. The use of autoluminescent bacteria also facilitates the determination of growth and inhibition kinetics. The method is cost-effective, can easily be adapted to a larger scale and is amenable to automation. Current efforts are directed towards applying this technology to drug screening in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.